


# PREVALENCE OF ALZHEIMER'S DISEASE



**Figure 1.** Statistics of Alzheimer's Disease Prevalence

Source: NHS Choices. (2016). *Alzheimer's Disease*. Retrieved from NHS Choices: [www.nhs.uk/conditions/alzheimers-disease/symptoms/](http://www.nhs.uk/conditions/alzheimers-disease/symptoms/)  
Dominguez et al., (2018). Prevalence of Dementia and Associated Risk Factors: A Population-Based Study in Philippines. *Journal of Alzheimer's Disease*. 63. pp. 1065-73.

## CHOLINERGIC PATHWAY PROMOTES NEURONAL CELL DEATH



**Figure 2.** General Pathway of Cholinergic Hypothesis towards Alzheimer's Disease (AD) Progression

B

Cholinesterase Inhibitor	Current Price	Advantages of Peptides-Based Therapeutics
<p><b>Donepezil</b></p> <p>Source: <a href="https://www.rosepharmacy.com/product-category/pharmacy/generic/d/donepezil-hcl/">https://www.rosepharmacy.com/product-category/pharmacy/generic/d/donepezil-hcl/</a></p>	<p>Php 62.50-162.00 (1 tablet= 10 mg)</p>	<ul style="list-style-type: none"> <li>▪ Naturally occurring biologics conferring <b>safety</b></li> <li>▪ <b>Greater efficacy, specificity and selectivity</b></li> <li>▪ Coordinates and harbors physiological processes</li> <li>▪ <b>Degrades into non-toxic metabolites</b></li> <li>▪ Diverse pharmacological functions</li> <li>▪ Lower manufacturing costs, higher stability and <b>greater activity</b></li> </ul> <p>Source: <a href="https://www.gesundheitsindustrie-bw.de/en/article/news/the-growing-significance-of-peptide-therapeutics">https://www.gesundheitsindustrie-bw.de/en/article/news/the-growing-significance-of-peptide-therapeutics</a></p>

AD-Related Studies	Peptide	Peptide Source	Pharmacological Activities
Cholinergic/ Neuroprotection	PhTx3-1	Phoneutria nigriventer	Memory improvement (Gomes et. Al, 2013)
	PhKv		Anti-AChE activity (Rigo et. al, 2017)
	PhTx4-5-5		Neuroprotective action against NMDA receptors (Silva et. Al, 2016)



*13<sup>TH</sup> PNHRS Week Celebration: Achieving Health-Related Sustainable Development Goals (SDGs) through Research and Innovation*

## **Cholinergic Inhibitory Characterization of Philippine Spider Venom from *Phlogiellus bundokalbo* for Purported Applications against Alzheimer's Disease**

*Presented by*

**SIMON MIGUEL M. LOPEZ**

*In collaboration with:*



**August 13, 2019**

**Limketkai Luxe Hotel, Cagayan de Oro City**

# RESEARCH OBJECTIVES & SIGNIFICANCE

## MAIN OBJECTIVE

To assess the cholinergic impact of Philippine spider venom from *Phlogiellus bundokalbo*

FRACTIONATE

CHARACTERIZE

EVALUATE CHOLINERGIC PROPERTIES

IN VITRO

IN SILICO

IN VIVO

## SIGNIFICANCE



Research to Enhance and Extend Healthy Lives

- Raising awareness on AD as NCD
- Establishing and integrating several factors leading to AD



Global Competitiveness and Innovation in Health

- Exploring for novel bioactive compounds for drug discovery and development
- Improve potency via OMICs technologies



Research in Equity and Health

- Spider venom for geriatric care



Conservation of Natural Resources

- Protection of spiders
- Education and transformation to become citizen scientists

## RESEARCH METHODOLOGY






Figure 4. Schematic Diagram of the Study

# *P. bundokalbo* contains several peaks indicating the presence of peptide-based compounds



**Figure 5.** The C18 RP-HPLC Profile of the crude spider venom suggests the presence of peptide-based compounds according to UV detection at 215 nm and 280 nm. Intense and faint purple colorations from crude and fractionated spider venom respectively. The crude venom concentration is equal to 5.73 mg/mL ( $\pm 0.338$ ) ( $R^2= 0.992$ ).

## Crude and fractionated spider venom contains compounds manifesting anti-AChE activities which exhibits competitive and uncompetitive inhibition





**Figure 6.** (a) Fractions exhibited anti-AChE show a kinetic curve below the untreated AChE reaction. (b) Fractions exhibited pro-AChE show a kinetic curve above the untreated AChE reaction. (c) Generally weak inhibition was observed of crude and fractionated spider venom in comparison to donepezil. (d) and (e) F1,F3,F16, crude venom and donepezil exhibited (un)competitive inhibitions (n=3).



## AChE Docking and Visualization Studies: Insights Towards Rational Drug Design of Venom-Peptide Inhibitors

Donepezil docking reveal certain binding interactions with the AChE active site.

Visualization of putative inhibition sites of spider venom peptides on AChE




**Figure 7.** (a) 3D and (b) 2D interaction diagram have shown that the drug has preferential binding in peripheral binding site and oxyanionic site of the AChE active site.

**Figure 8.** (a) Overlaid and (b) individual visualizations reveal certain putative regions of AChE where the binding of spider venom peptides may happen to exhibit conformational change-induced enzyme inhibition (Roca et al., 2018).

## Different degrees of locomotion were observed after administration of donepezil and spider venom on *Zophobas morio* larvae.

Locomotion Assay of *Z. morio* Larvae




### Parameters Observed

Rate of forward and backward movements

### Scoring:

- 4 - Severe continuous movements, larvae dies
- 3 - Continuous, rapid movements
- 2 - Sporadic movements
- 1 - Little to no movements



**Figure 9.** Downward trend was observed on donepezil and spider venom upon metathoracic administration on *Z. morio* larvae in comparison with 0.9% NSS. This could be attributed to cholinergic inhibition which is manifested on different degrees of motility on the larvae (n=3).

# Proposed Cholinergic Action of Donepezil and Spider Venom from *P. bundokalbo*




Figure 10. Cholinergic Role of Spider Venom to Cholinergic Nervous System

# Conclusions and Recommendations

- Crude and fractionated spider venom from *P. bundokalbo* contains various peptides which exhibited cholinergic impact as supported by *in vitro*, *in silico* and *in vivo* studies.
- May exhibit therapeutic potential against AD as an AChE inhibitor.



**Dose-dependent evaluation** of the crude and fractionated venom



**Further optimization and purification** of the peaks which cannot be separated by one round of RP-HPLC



**Structural elucidation** of the venom fractions exhibiting AChE inhibitory activities for purported use against AD.



**Integrate the AChE inhibitory results** of spider venom *in vitro* to transgenic model organisms preferably with hallmarks of **Alzheimer's disease *in vivo***

## Acknowledgement:

